Breaking Down SG&A Expenses: Perrigo Company plc vs Protagonist Therapeutics, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Perrigo Company plc and Protagonist Therapeutics, Inc. offer a fascinating study in contrasts. From 2014 to 2023, Perrigo's SG&A expenses have shown a steady upward trend, increasing by approximately 89% over the decade. In 2014, their expenses were around 675 million, climbing to nearly 1.275 billion by 2023. This growth reflects Perrigo's expansive operations and strategic investments.

Conversely, Protagonist Therapeutics, Inc., a smaller player, has seen its SG&A expenses grow from a modest 1.86 million in 2014 to over 33 million in 2023, marking an impressive 1,700% increase. This surge underscores the company's aggressive growth strategy and scaling efforts. As these companies navigate the competitive landscape, their SG&A expenses reveal much about their operational priorities and market positioning.